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Abstract
Erythropoietin can be over-expressed in skeletal muscles by gene electrotransfer, resulting in 100-fold increase in serum EPO
and significant increases in haemoglobin levels. Earlier studies have suggested that EPO improves several metabolic
parameters when administered to chronically ill kidney patients. Thus we applied the EPO over-expression model to
investigate the metabolic effect of EPO in vivo. At 12 weeks, EPO expression resulted in a 23% weight reduction (P,0.01)
in EPO transfected obese mice; thus the mice weighed 21.960.8 g (control, normal diet,) 21.961.4 g (EPO, normal diet),
35.363.3 g (control, high-fat diet) and 28.862.6 g (EPO, high-fat diet). Correspondingly, DXA scanning revealed that this
was due to a 28% reduction in adipose tissue mass. The decrease in adipose tissue mass was accompanied by a complete
normalisation of fasting insulin levels and glucose tolerance in the high-fat fed mice. EPO expression also induced a 14%
increase in muscle volume and a 25% increase in vascularisation of the EPO transfected muscle. Muscle force and stamina
were not affected by EPO expression. PCR array analysis revealed that genes involved in lipid metabolism, thermogenesis
and inflammation were increased in muscles in response to EPO expression, while genes involved in glucose metabolism
were down-regulated. In addition, muscular fat oxidation was increased 1.8-fold in both the EPO transfected and
contralateral muscles. In conclusion, we have shown that EPO when expressed in supra-physiological levels has substantial
metabolic effects including protection against diet-induced obesity and normalisation of glucose sensitivity associated with
a shift to increased fat metabolism in the muscles.
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Introduction
Erythropoietin (EPO) was introduced for clinical use in 1989 in
the treatment of end-stage renal disease (ESRD). These early
clinical trials showed that EPO increased exercise capacity and
activity levels, improved sleep-wake cycles, increased body
warmth, and improved appetite and quality-of-life [1]. Later
studies showed that EPO treatment also tended to lower BMI and
increase underarm muscular area [2,3]. In fact Allegra and
colleagues showed that EPO treatment lowered BMI, LDL, and
apolipoprotein B significantly if the patients did not increase their
food intake, while this effect was abrogated if food intake was
increased [3]. Furthermore it has been shown that leptin, which is
secreted by the adipose tissue in proportion to the fat stores [4], is
significantly decreased after 3 to 6 months of EPO treatment [5]
suggesting a fat reducing effect of EPO. Other trials with EPO
administration to diabetic, chronic renal diseased patients have
shown that EPO significantly improves several metabolic param-
eters including fasting glucose level and insulin sensitivity as
measured by euglycaemic hyperinsulinaemic clamp and intrave-
nous glucose tolerance test [6,7].
To our knowledge, no formal study of EPO administration to
obese patients has been undertaken. However in an altitude study,
22 obese male subjects with metabolic syndrome were relocated
from 500 to 1700 metres above sea level for 3 weeks [8]. During
the sojourn, plasma EPO and reticulocyte count, but not plasma
haemoglobin increased significantly, and a decrease in body mass
was observed, which was mainly due to a reduction in body fat [8].
The subjects also showed significant improvements in the glycemic
parameters such as glucose tolerance and insulin resistance [9].
The aim of the present study was to test the hypothesis that
over-expression of EPO in mice fed a high fat diet could a) reduce
fat accumulation, b) improve diet-induced insulin resistance, and
c) normalise glucose tolerance.
Over-expression of EPO was obtained by electrotransfer of
cDNA coding for EPO to the tibialis cranialis (TC) muscle.
Transfer by electric pulses is obtained when an external electric
field transiently destabilises the membrane rendering the cells
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successful in vivo DNA electrotransfer of EPO into skeletal muscles
in both mice [11–13] and rats [14,15] with EPO expression and
elevations in the haemoglobin levels being detected more than a
year after DNA electrotransfer in mice [16]. In addition, it has
been shown that EPO expression and thus haemoglobin levels can
be tightly regulated through a doxycycline-inducible regulatory
system [17]. This model was used in the present study to generate
a transient conditional transgenic EPO mouse model.
Results
Conditional EPO expression from skeletal muscles after
DNA electrotransfer
Transient conditional transgenic EPO mice were generated by
transferring 1 mg plasmid encoding EPO under control of the
doxycycline-responsive element (TRE), 1 mg of plasmid encoding
the reverse tetracycline transactivator (rtTA), and 1 mg of plasmid
encoding the tetracycline-dependent silencer (tetS) into the right
tibialis cranialis muscle by DNA electrotransfer. After treatment
the mice were placed on either a normal chow or a high-fat
(60 kcal% fat) diet. Treatment of the transfected mice with
doxycycline, which induces expression, resulted in significant
increases in Hgb levels, peaking 6 weeks after transfection in both
lean (14.760.4 mmol/l, P=3.4*10
29, n=8) and high-fat fed mice
(14.260.6 mmol/l, P=1.8*10
26, n=8) (Control: 8.460.1 mmol/
l). A weekly injection of 10 mg/kg recombinant human EPO
(rhEPO), induced similar increases in Hgb levels (lean:
14.060.3 mmol/l, P=8.9*10
210, n=8; high-fat fed:
13.360.3 mmol/l, P=5.7*10
28,n = 8 ,Fig. S1). After 12 weeks
of weekly EPO injections, the Hgb levels dropped to baseline level,
while the Hgb levels in the EPO electrotransferred mice remained
elevated. The iron levels in the EPO injected mice were
significantly higher than in the EPO transfected mice, indicating
a high turn-over of red blood cells in the groups receiving rhEPO
(Fig. S1).
Serum EPO increased from the basal level of 0.0460.003 pg/ml
to 2.3960.4 pg/ml (P=0.033, n=8) within the first 2 weeks after
DNA electrotransfer, equivalent to an increase in mean Hgb from
8.260.1 to 11.860.2 mmol/L (P=7.8*10
27, n=8). The corre-
sponding EPO concentration was 13906117 pg/mg muscle in the
transfected muscle, 1263 pg/mg muscle in the contralateral
control muscle, and 1.060.1 pg/mg muscle in the muscles of
control mice. Thus, the EPO concentration in the transfected
muscle was 500 times higher than the level reached systemically.
EPO expression diminishes fat mass in diet-induced
obese mice
Mice from both dietary groups were weighed weekly after EPO
transfer and induction of gene expression by dox administration.
In the high-fat fed groups, EPO expression significantly decreased
the weight gain with up to 75% (P=0.0024, n=8) in the first 30
days (Fig. 1A). In fact, there were no differences in body weight
between the EPO transfected high-fat fed mice and mice receiving
normal chow (P=0.23, n=8). After 40 days, body weight started
to increase in the high-fat fed EPO group compared to mice
receiving normal chow. This was correlated with a decrease in the
Hgb levels from 13.061.8 mmol/l to 11.463.2 mmol/l, suggest-
ing a reduction in the EPO expression.
Importantly, there were no differences in the food intake in the
high-fat fed mice between the control (2.52 g/mouse/day) and
EPO transfected groups (2.91 g/mouse/day), or between the
Figure 1. EPO expression diminishes diet-induced fat accumulation. One mg of EPO plasmid and each of the regulatory plasmids, pTet-On and
pTetS, were electrotransferred into the right tibialis cranialis muscle of C57Black/C mice. Each group consisted of 8 mice and the mice were placed on
either regular chow or a high-fat diet. Means6SEM are depicted. A) Body weight of the EPO transfected mice. For the first 14 weeks transgenic EPO
expression was induced by administration of doxycycline in the drinking water, whereafter the doxycycline was withdrawn for the rest of the
experiment.B)Foodintake forthe animals in A).C)Fatmass andlean bodymass inthehigh-fatfed micemeasuredbyDXAscanning12weeksafterDNA
electrotransfer. D–F) Weight of abdominal fat, subcutaneous fat and spleen 12 weeks after DNA electrotransfer. Statistical significance was testedb y
Student’s t-test with Bonferroni corrections for multiple testing. * indicates significance at p,0.05, while ¤ indicates significance at p,0.01.
doi:10.1371/journal.pone.0005894.g001
EPO Protects against Obesity
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e5894control (2.83 g/mouse/day) and EPO transfected groups (3.72 g/
mouse/day) placed on a regular diet (Fig. 1B).
The high-fat fed EPO transfected mice appeared noticeably
leaner than control mice fed the same diet. To assess the body
composition of the high-fat fed mice, a DXA scanning was
performed 12 weeks after EPO electrotransfer (Fig. 1C). The
EPO transfected mice had 28% lower amounts of adipose tissue
than the control mice (P=0.012, n=8), while no difference in lean
body mass was observed (P=0.83, n=8).
A quantitative analysis of fat-pads and organ masses revealed
that high-fat feeding led to significant increases in abdominal and
subcutaneous adipose weight (Fig. 1D–E). EPO expression in the
high-fat fed mice resulted in 44% (P=0.0004, n=8) and 37%
(P=0.002, n=8) reductions in the masses of the abdominal and
subcutaneous fat pads, respectively. The reduction in adipose
tissue mass was partial in this model as the high-fat fed EPO
transfected mice still had appreciably more adipose tissue mass
than lean control mice. EPO expression in mice fed a normal
chow diet also led to a small, but reproducible decrease in
abdominal fat-pad mass (P=0.021, n=8). In both EPO
transfected groups, the spleens were enlarged due to increased
turnover of erythrocytes (Fig. 1G). No significant changes in the
weights of liver and heart were observed (Fig. S2).
Muscle hypertrophy after EPO electrotransfer
To examine the phenotypic consequences of EPO expression on
the transfected muscle, mice were electrotransferred with EPO in
1 leg and received a chow diet and doxycycline for 5 weeks. As
shown in Fig. 2A, EPO expression induced significant increases in
muscle mass in the transfected muscles compared to the contra
lateral control muscle (P=0.046, n=8) and muscles from
untreated control mice (P=0.00015, n=8). The increase in
muscle weight tended to correlate positively with the Hgb level
(P=0.078, n=10). The contra lateral muscles tended to weigh
more than the control muscles (P=0.086). The total protein
concentration per g muscle remained unchanged, indicating that
the increased muscle volume was due to hypertrophy and not
edema formation (data not shown). Electroporation alone did not
have any effect on muscle mass (data not shown).
To elucidate the molecular event leading to increased muscle
mass, we investigated the level of phosphorylated Akt, which is an
important inducer of muscle hypertrophy, and several muscular
transcription factors. We found that EPO over-expression
significantly increased the phosporylation of Akt (Fig. 2B) and
induced a 4-fold increase in the expression of myogenin at 5 weeks
(data not shown). At this time point, EPO expression did not
induce any of the muscular transcription factors, MyoD1, Myf5
and myostatin (data not shown). Despite the increased muscle
mass, EPO expression had no effect on maximal force or stamina,
which did not differ between electroporated, sham, or EPO
transfected muscles (Fig. 2D).
Expression analysis of heavy myosin chain (MHC) proteins
revealed that MHCI was up-regulated in the EPO transfected
muscles (Fig. 2C), suggesting that the hypertrophic response
might primarily be associated with Type I muscle fiber
hypertrophy.
Increased vascularisation of muscles in EPO transfected
mice
In agreement with the reported angiogenic effects of EPO, we
found an increase in the number of CD31 positive vessels in both
the EPO transfected (20.061.0) and the contralateral muscles
(20.762.3) compared to control muscles from untreated mice
(15.562.1) (Fig. 3). Evaluation of expression of the angiogenic
factors, VEGF-1A and VEGF-1B, showed that these were not
elevated in the EPO transfected muscles (data not shown).
EPO expression normalises metabolic parameters in diet-
induced obese mice
Next, the effect of transgenic EPO expression on metabolic
parameters after 12 weeks of doxycycline induction was examined.
There were no differences in fasting glucose between the
experimental groups of animals (Fig. 4A). Fasting serum insulin
was significantly increased in high-fat fed control mice
(P=9.3*10
28, n=7), while insulin levels were normalised by
EPO transfection in the high-fat fed mice (P=0.42, n=7)
compared to normal chow fed control mice (Fig. 4B). A reduction
in fasting total cholesterol in the chow-fed EPO transfected mice
was observed (p=0.022, n=8) (Fig. 4C), while no differences
were observed between the high-fat fed groups. Serum levels of
fasting triglycerides, HDL and LDL did not differ significantly
between the experimental groups (data not shown).
Glucose and insulin tolerance tests were performed on the
different experimental groups (Fig. 4D–E). EPO expression in the
high-fat fed mice normalised the glucose disposal rate compared to
the lean control mice (P=0.73, n=8), while no difference in
glucose sensitivity was observed between the lean groups. In
contrast, neither high-fat feeding nor EPO expression had any
effects on insulin sensitivity, although a slower decrease in blood
glucose in the EPO transfected mice was observed at 15 min for
both dietary groups (P=0.018 and 0.007, respectively) (Fig. 4E).
As the mice were injected with insulin per body weight, the high-
fat fed mice received more insulin, and therefore also experienced
a larger drop in blood glucose. Adjusting for injected insulin, did
not results in any significant differences between control and EPO
transfected mice. In the high-fat fed groups, the insulin tolerance
test was stopped at 60 min as some of the mice developed tremor.
Next, serum levels of selected cytokines and hormones were
analysed (Table 1). Resistin was normalised in the EPO
transfected high-fat group to the level observed in the lean groups.
Leptin and tPAI-I levels were increased in both high-fat groups
with no effect of EPO expression. TNF-a and IL-6 were not
induced to detectable levels in any of the groups (data not shown).
Body composition changes caused by transgenic EPO
expression are reversible
To examine whether the effects of EPO expression on body mass
were reversible, mice were administered doxycycline for 14 weeks,
which was then withdrawn for 14 weeks. After 14 weeks of
doxycycline withdrawal, Hgb levels had returned to controllevel for
both lean mice (8.060.1 mmol/l, n=8) and high-fat fed mice
(8.260.2 mmol/l, n=8).The initial EPO-induced decrease inbody
weight in the high-fat fed group was reversed after withdrawal of
doxycycline, and the weight gain in the EPO transfected group
resumed the same rate as the control group (Fig. 1A). A glucose
tolerance test showed that the normalisation of glucose disposal rate
during EPO expression was reversed with the mice exhibiting the
same impaired glucose sensitivity as the high-fat fed control group
(p=0.90,n=8)(Fig.S3).Nodifferencesineitherfasting glucose,or
total cholesterol, triglycerides, HDL, or LDL levels were observed
between the groups (data not shown).
Early changes in fasting insulin after EPO expression
In our model the mice develop high levels of Hgb. To
circumvent this we investigated the early changes before the
Hgb levels increased, as well as the effects of electrotransfer of a
mutant form of EPO, which does not cause Hgb to increase.
EPO Protects against Obesity
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electrotransfer. At this point, Hgb levels had increased to around
10.5 mmol/l, and serum EPO concentration was increased 40–
fold (Table 2). In the high-fat fed EPO transfected mice, fasting
insulin levels were significantly reduced (p=0.012, n=8), while no
differences were observed in fasting glucose levels or glucose
sensitivity. No effects on fasting insulin, glucose, or glucose
sensitivity were observed in the lean mice.
Figure 2. EPO expression is associated with muscle hypertrophy. The muscle hypertrophic response was evaluated 5 weeks after DNA
electrotransfer in mice placed on the regular chow diet. Each group consisted of 8 mice. For A and B, data from muscles from control mice (control),
the contra lateral leg of the EPO transfected mice (contralateral), and the EPO transfected leg (EPO) are shown. Means6SEM are depicted. A) Total
muscle weight, B) phosporylated Akt determined by Western Blotting, C) expression of muscle fibre protein (Q-PCR) in control and EPO transfected
muscles, and D) muscle stamina in % of the control leg. Statistical significance was tested by Student’s t-test with Bonferroni corrections for multiple
testing. * indicates significance at p,0.05.
doi:10.1371/journal.pone.0005894.g002
Figure 3. EPO increases vascularisation in the transfected muscle. Histological sections were performed from muscles excised 5 weeks after
DNA electrotransfer and stained with CD31. A) Mean number of capillaries per muscle section (n=8, mean6SEM), and representative pictures of
histological sections of B) control muscle, C) contra lateral muscle, and D) EPO transfected muscle. Statistical significance was tested by Student’s t-
test with Bonferroni corrections for multiple testing. * indicates significance at p,0.05.
doi:10.1371/journal.pone.0005894.g003
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binding site (aa 46: VRD and aa 50: ARE) resulted in a 36%
increase in the muscle mass of the transfected muscle, and a slight
reduction in the total body weight 12 weeks after transfection. As
evaluated by DXA scanning, there were no changes in the total fat
mass in these mice.
EPO expression induces increased lipid oxidation and
inflammatory markers in muscle
To assess the molecular mechanisms by which EPO over-
expression diminishes fat mass and normalises metabolic parame-
ters in diet–induced obese mice, PCR arrays on metabolic genes
were performed on muscle samples from EPO transfected and
control mice from both dietary groups. In addition, C-14 palmitate
oxidation was measured directly in muscle homogenates. Analyses
were performed at 1 week and 12 weeks after DNA electrotransfer.
Among the 99 analysed genes, EPO transfection resulted in up-
regulation of 12 genes and down-regulation of 15 genes after one
week, independent of dietary group. To evaluate the differences
between functional related genes a gene ontology analysis was
performed (Fig. 5). Genes involved in thermogenesis, cytoskeleton
and inflammation were up-regulated in response to EPO
expression, whereas genes involved in glucose metabolism and
transport, proteolysis, stress response, and DNA repair were down-
regulated. In agreement with the reduced plasma insulin levels in
the high-fat fed EPO mice, genes involved in signalling such as
insulin, IRS1 and insulin degrading enzyme were down-regulated
in this group. In contrast, genes involved in lipid metabolism,
Figure 4. EPO improves glucose tolerance in high-fat fed mice. Twelve weeks after EPO electrotransfer A) fasting glucose, B) fasting insulin,
and C) fasting total cholesterol were determined, and D) a glucose tolerance test and E) an insulin tolerance test were performed. Means6SEM for
groups of 8 mice placed on either a regular chow or high-fat diet are depicted. Statistical significance was tested by Student’s t-test with Bonferroni
corrections for multiple testing. * indicates significance at p,0.05.
doi:10.1371/journal.pone.0005894.g004
Table 1. Serum levels of metabolic hormones.
Parameter Normal diet High-fat diet
Control EPO P-value Control EPO P-value
Leptin (pg/ml) 6076166 6996193 0.71 25384612703 1176662890 0.25
MCP-1 (pg/ml) 21.262.3 59.6612.3 0.104 61.3622.3 72.3612.2 0.66
Resistin (pg/ml) 443961033 36916670 0.53 831561479 37296528 0.048
tPAI-I (pg/ml) 30336529 23086410 0.27 820762361 73266883 0.74
Means6SEM of selected hormones in serum after 12 weeks of EPO expression (n=8 in each group). Statistical significance is tested by Student’s T-test with Bonferroni
correction for multiple testing.
doi:10.1371/journal.pone.0005894.t001
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up-regulated in the high-fat EPO group.
At 12 weeks, fewer genes were differentially expressed in
response to EPO transfection. Three genes (Ccl5, Neurod1, TNF-
a), which were all annotated to inflammation, were up-regulated,
while 2 genes (PPAR-a, PGC-1a) were down-regulated. EPO
attenuated a high-fat feeding-induced increase in several genes e.g.
fructose bisphosphatase, forkhead box G1, and Snap23.
After one week, fat oxidation increased by 64% in the EPO
transfected muscles compared to control muscle for both dietary
groups (normal: p,0.05, high-fat: p,0.001, n=8, Fig. 6).
Similarly, fat oxidation was increased by 63% and 58% in the
contralateral muscle of the EPO transfected mice for the normal
and high-fat fed groups, respectively (p,0.05 for both groups,
Fig. 6). The oxidative capacity did not differ between the EPO
transfected and contralateral muscles, showing that EPO expression
in one muscle increases fat oxidation in the whole musculature.
Discussion
In the present study, we show that over-expression of EPO
protects against diet-induced obesity and improves metabolic
parameters in obese mice. These effects were associated with
EPO-dependent muscle hypertrophy and increased vascularisation
of the muscles. Moreover, EPO expression increased fat oxidation
in the muscles and increased the expression of genes involved in
lipid metabolism and reduced the expression of genes involved in
insulin signalling in the high-fat fed mice, showing that EPO
expression shifts the muscular metabolism towards increased fat
oxidation.
EPO over-expression by DNA electrotransfer
We used DNA electrotransfer to over-express EPO selectively in
just one muscle i.e. m. tibialis cranialis. In accordance with
previous work, EPO electrotransfer to this rather limited amount
of tissue was sufficient to induce significant increases in both serum
EPO and haematocrit levels [11–13]. In our hands, EPO
electrotransfer induced the same increase in haematocrit as can
be obtained with injections of rhEPO. However the electrotransfer
method has the advantage of continuous release of endogenous
murine EPO. Although electrotransfer utilises a transient break-
down of the cell membrane, we have used electric pulses, which
have been extensively characterised to ensure minimal adverse
Table 2. Early changes in metabolic parameters one week after EPO electrotransfer.
Normal diet High-fat diet
Control EPO P-value Control EPO P-value
Hgb (mmol/l) 7.660.3 10.460.5 0.0002 8.460.2 10.760.3 6.5E-6
Serum EPO (pg/ml) 52610 19406400 0.0007 3969 16646338 0.0003
Fasting glucose (mmol/l) 4.160.2 3.760.3 0.22 6.260.6 5.060.3 0.098
Fasting insulin (pg/ml) 8476170 6996233 0.62 18616337 8366126 0.012
Glucose sensitivity (AUC) 1991651 2076692 0.44 1459629 1379642 0.14
Means6SEM of Hgb, serum EPO, fasting glucose and insulin, and glucose sensitivity one week after EPO electrotransfer (n=8 in each group). Statistical significance is
tested by Student’s T-test with Bonferroni correction for multiple testing.
doi:10.1371/journal.pone.0005894.t002
Figure 5. EPO induced changes in muscle gene expression one week after electrotransfer. Significantly differentially expressed genes are
depicted according to gene ontology groups. Control and EPO transfected groups were fed either a normal chow or a high-fat diet for one week. Mean
Ctthresholdisdepictedforeach groupandredcorrespondstoahigh expression value;greenindicates a lowerexpressionvalue (n=4–5ineach group).
doi:10.1371/journal.pone.0005894.g005
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survival and function [18–20].
The metabolic role of EPO over-expression
The main finding is that muscular EPO over-expression
protects mice against diet-induced obesity. This weight reduction
is followed by a normalisation of several metabolic parameters
including diet-induced glucose intolerance in the high-fat fed EPO
transfected mice. The effects are reversible as increased weight
gain and impairment of the metabolic parameters i.e. glucose
tolerance are observed after withdrawal of the inducible EPO
expression.
Our results show that the mechanism for EPO-induced
protection against obesity is through increased fat oxidation as
determined directly and by regulation of muscular gene expres-
sion, in particular inducing genes involved in lipid metabolism and
glyconeogenesis and decreasing glucose metabolism in the high-fat
fed mice. In support of this Davenport et al showed that 14 weeks
of EPO administration in haemodialysis patients increased muscle
glycogen content and lowered muscle fat content [21], while Cayla
et al. showed that EPO induces a shift in muscle fibre composition
from fast glycolytic fibres to slow oxidative fibres [22]. This
suggests that EPO is indeed involved in shifting muscle
metabolism towards increasing fat oxidation. Moreover, we also
found that EPO induced an increased expression of genes involved
in thermogenesis. This correlates well with the findings of Fagher
et al., who showed that EPO increases heat production in muscles
from haemodialysis patients as measured by direct calorimetry
[23]. We have in our current set-up not been able to measure
energy expenditure in the EPO transfected mice. Yet the increases
in genes involved in thermogenesis in our study suggest that in
addition to the increased fat oxidation, increased heat production
could play a role in the elevated energy expenditure in the EPO
transfected mice.
In the present study, we have measured glucose and insulin
tolerance after 12 weeks. At this point the EPO transfected mice
had accumulated significantly less adipose tissue than the control
mice. EPO expression induced a normalization of glucose
tolerance in the high-fat fed mice, while no differences in the
insulin sensitivities were observed between the control and EPO
transfected mice. The normalization observed in glucose tolerance
could most likely be an indication of reduced adipose deposits
rather than a direct effect of EPO on glucose disposal rate. This is
supported by the down-regulation of genes involved in glucose
metabolism, showing that the main effect of EPO most likely to
due to the increased overall fat oxidation. The finding that the
glucose response to glucose tolerance test is much higher in the
high-fat fed controls, also suggests that these have impaired insulin
secretion, when challenged with glucose, and that EPO over-
expression counteracts this impairment. Our study was not
designed to unravel mechanisms underlying altered glucose
metabolism. However, although speculative, one explanation
could be that EPO influences gut hormones and their effect on
insulin secretion.
EPO over-expression induced muscle hypertrophy and
capillarisation
We also show that EPO expression induced muscle hypertrophy
as measured by increased muscle weight, while no changes in the
amount of protein per muscle weight were observed. The
hypertrophic response was most pronounced in the transfected
muscle, but we also observed a borderline increase in muscle mass
in the contra lateral muscles. Lundby et al. have shown that the
EPO receptor is expressed in skeletal muscles in the sarcolemma
[24], indicating a physiological role for EPO on muscle tissue.
EPO receptor activation leads to stimulation of the signal
transducer and activator of transcription (STAT) 5, which
activates PI3 kinase and Akt [25]. Akt activation plays an
important role in transcription and cell proliferation. We find
activation of Akt in both the EPO transfected and contra lateral
muscles, suggesting that the hypertrophic response in the muscles
is mediated through the STAT-Akt signalling pathway. Interest-
Figure 6. EPO over-expression increases exogenous palmitate oxidation. One week after EPO electrotransfer C-14 palmitate oxidation was
measured in muscle homogenates from transfected muscle, the contralateral tibialis cranialis muscle of the same mouse and control muscle from
non-transfected animals. Statistical significance was tested by Student’s t-test with Bonferroni corrections for multiple testing. * indicates significance
at p,0.05, while ¤ indicates significance at p,0.01.
doi:10.1371/journal.pone.0005894.g006
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showed a similar phenotype as our EPO expressing mice with
muscle fibre hypertrophy, resistance to diet-induced obesity and
significant improvements in several metabolic variables including
glucose tolerance [26]. In our study, we did not find any increases
in muscle force. This can be explained by the selective induction of
oxidative muscle fibres, which do not specifically add to the
maximal contractile force.
The scientific evidence for a role for EPO in promoting
angiogenesis in tissues undergoing growth or repair is quite clear
[27]. The EPO receptor is located on endothelial cells and cell
culture studies with vessels have shown that EPO has direct
proliferative effects on endothelial cells [28]. In line with this we
find that EPO expression induces increased vascularisation in both
the EPO transfected and the contra lateral muscles. The increase
in blood supply may play an important role in providing oxygen
for the increased oxidative metabolism observed in the muscles.
Supra-physiological levels of EPO and metabolic effects
Little information on EPO’s effect in obese subjects is available
due to concern about EPO’s role in promoting cardiovascular
disease by increasing the haematocrit level and blood pressure in
these patients. And in fact we do not believe that our findings are
translational to therapeutic applications with native EPO. In our
current model, EPO over-expression leads to hematocrit increases
even when scaling down the EPO plasmid concentration to
0.25 mg.
New non-haematological EPO agents have been developed
primarily for treatment of ischemic stroke [29]. These agents
possess all the pleiotropic effects of EPO without raising the
haematocrit level. Human EPO consists of a classic four-helix
bundle cytokine motif with 2 distinct receptor binding sites. These
include 1) a high affinity binding site that involves residues at the
helix D:AB loop interface, and 2) a low affinity receptor binding
site that lies within the AC helical bundle. The high affinity
binding site mediates binding to the homodimer EPO receptor
and is responsible for the haematopoietic response, while the low
affinity binding site mediates binding to the EPO receptor -
common b receptor heterotrimer complex, a interaction, which
has been proposed to be responsible for the pleiotropic effects of
EPO [30]. We have generated an EPO analogue with mutations
in the high affinity binding site for the homodimer EPO receptor,
which is responsible for the hematological response. Electrotrans-
fer of this EPO analogue induced muscle hypertrophy and
moderate reductions in body weight. However, the EPO analogue
was not able to prevent accumulation of adipose tissue. It should
be noted that our study used murine EPO, and thus further studies
are warranted to fully understand the metabolic sites on both
murine and human EPO.
EPO secretion from the muscle
Recently the skeletal muscle was identified as an endocrine
organ that produces and releases a number of biologically active
substances, known as myokines [31]. These myokines participate
in cell-to-cell and organ-to-organ cross-talk and may be involved
in mediating the health beneficial effects of exercise and play
important roles in the protection against diseases associated with
low-grade inflammation, insulin resistance, and hyperlipidemia
such as cardiovascular diseases, type 2 diabetes, and cancer [31].
In our study EPO mimics a myokine in that it is produced and
secreted from skeletal muscles and exhibits paracrine and
endocrine effects on other muscles. So far no one has been able
to show that EPO is secreted from muscles in response to exercise.
Contrarily a swimming study showed that serum EPO actually
decreased after a training bout [32]. Thus even though we have
utilised the DNA electrotransfer method to over-express and
secrete EPO from muscles it does not prove that EPO is indeed
secreted natively from muscles.
Conclusion
We have shown that over-expression of EPO protects against
diet-induced obesity and this reduction in weight gain was
associated with improvement of metabolic parameters in high-fat
fed mice in particular increased fat oxidation in the muscles. In
addition we found that EPO expression induced muscle
hypertrophy and increased capillarisation. Although the strategies
used in this study show that haematological and metabolic effects
of EPO cannot be separated, they open a new avenue for the
development of EPO versions to counteract metabolic syndrome
without exacerbated and undesired hematocrit increase.
Materials and Methods
Animals and muscle preparation
All animal experiments were conducted in accordance with the
recommendations of the European Convention for the Protection
of Vertebrate Animals used for Experimentation and after
permission from the Danish Animal Experiments Inspectorate.
Animal experiments were performed on eight to ten weeks old
female C57Black/C mice from Taconic (Tornbjerggaard, Den-
mark), while force measurements were performed on 4-week-old
Wistar rats. The mice were maintained in a thermo-stated
environment under a 12-hour light/dark cycle with free access
to food and drinking water. The mice were fed either a standard
maintenance diet (normal chow, 2844 kcal/kg, 4% crude fat,
Altromin pellets, Spezialfutter-Werke, Germany) or a high-fat diet
containing 60 kcal% fat (high fat, 5240 kcal/kg, 34.9% crude fat,
D12492, Research Diets, Bomholtgaard, Denmark). Food and
water were weighed daily and consumption calculated. The
animals were killed by cervical dislocation, and intact tibialis
cranialis (TC) muscles were excised and quickly frozen on dry ice
and absolute alcohol. The subcutaneous fat deposits were dissected
by removing the encapsulated fat pad located in the right flank;
while the abdominal fat deposits were isolated by insertion into the
peritoneal cavity and dissecting out the fat pad associated with the
uterus and ovaries. The adipose tissue was then isolated from the
non-adipose structures. Moreover, the dorsal fat compartments
around the kidneys were cleaned for adipose tissue. Together these
compartments constitute the abdominal fat mass.
Plasmid constructs and in vivo DNA electrotransfer
The plasmids pTet-On, encoding the rtTA transactivator
[33,34], and pTetS, encoding the tS silencer [35], were both
obtained from Clontech (Palo Alto, CA, USA). pBI-mEPO
encoding murine EPO under the control of an rtTA-dependent
promoter was kindly provided by Dr. Fattori. A mutated form of
EPO was designed by changing amino acid 46 from V to D and
amino acid 50 from A to E, and the construct was cloned into the
pBI vector. All DNA preparations were performed using Qiafilter
Plasmid Maxiprep kits (Qiagen, Germany), and the concentration
and quality of the plasmid preparations were controlled by
spectrophotometry and gel electrophoresis.
The animals were anaesthetised 15 min prior to DNA
electrotransfer by i.p. injection of Hypnorm (0.4 ml/kg, Janssen
Saunderton, Buckinghamshire, UK) and Dormicum (2 mg/kg,
Roche, Basel, Switzerland). The plasmid solution (1 mg of each
plasmid in 20 ml of PBS) was injected i.m. along the fibres into the
TC muscle using an 29G insulin syringe. Plate electrodes with a 4-
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electrode and skin was ensured by hair removal and use of
electrode gel. The electric field was applied using a Cliniporator
TM
(IGEA, Italy), applying a combination of a high voltage (800 V/
cm (applied voltage=320 V), 100 msec) pulse followed by a low
voltage (100 V/cm (applied voltage=40 V), 400 ms) pulse
[18,20]. Induction of gene expression was obtained by adminis-
tering drinking water consisting of distilled water containing
various concentrations (0.01–0.2 mg/ml) of doxycycline (doxycy-
cline hyclate, Sigma-Aldrich, Denmark) [36]. Control mice were
untreated, but received doxycycline in the drinking water.
Evaluation of body composition by DXA scanning
Twelve weeks after transfection, anaesthetised mice were DXA
scanned in a LUNAR Prodigy scanner with software version 8.10
(GE Healthcare Systems, LUNAR, Madison WI, U.S.A.) using the
small animal software application. Each group of eight mice was
placed closely together in the scanner (in order to reduce the inter-
individual variance) and scanned 12 times (to reduce the inter-
observational variance). The collected data were analysed by
mapping each mouse and extracting individual data for this mouse
by local region analysis.
Protein measurements
Total muscle protein was extracted by tissue homogenisation in
a HEPES-EDTA buffer containing 12 mM Na pyrophosphate,
100 mM NaF, NaV and proteinase inhibitors. Protein content was
determined by a colorimetric assay (BioRad, Denmark). Equal
amounts of protein (25 mg) were separated by a 4–12% SDS
PAGE gel (invitrogen) under reducing conditions and then
transferred to PVDF membrane (GE healthcare). The membrane
was blocked with 5% non-fat milk for one hour at room
temperature, and after washing it was incubated over night (4
Cu) with either anti-Akt (1:2000 cell signalling) or anti- phospho-
Akt (1:1000 cell signalling) antibodies in 5% BSA. After washing
the membrane was incubated with goat anti rabbit IgG antibodies
(1:10.000 DAKO) in 5% non-fat milk for one hour at room
temperature. For detection, the membrane was incubated with
super signal west femto luminol/enhancer solution (thermo
scientific) for 3 minutes, and the proteins were visualized using a
charge-coupled device camera (BioRad) and quantified with
Quantity One (Bio Rad).
Histology
Forty-eight hours after treatment muscles were isolated, fixed in
1 ml formalin buffer, and embedded in paraffin blocks following
standard procedures. Sections 3–5 cm thick were stained with
hematoxylin and eosin (Mayer-Sour) or with alkaline phosphata-
seconjugated CD31 antibodies followed by counterstaining with
Mayer’s hematoxylin.
Measurement of force
Force was measured as previously described in detail by Clausen
& Everts [37]. In brief, isolated EDL muscles were mounted
vertically with their tendons intact on a force displacement
transducer (Grass FT03, W.Warwick, RI, USA) for isometric
contractions in thermostatically controlled (30uC) chambers
containing standard Krebs-Ringer bicarbonate buffer (pH 7.3)
with (in mM): 122.1 NaCl, 25.1 NaHCO3, 2.8 KCl, 1.2 KH2PO4,
1.2 MgSO4, 1.3 CaCl2, and 5 D-glucose and gassed continuously
with a mixture of 95% O2 and 5% CO2. Direct electrical
stimulation was delivered via platinum electrodes on either side of
the mid-portion of the muscle. Muscle length was adjusted to
optimal length during repeated stimulation with single pulses.
Finally force was checked using short tetanic contractions induced
by supramaximal 1 ms pulses of 10 V at 90 Hz for 0.5 sec.
Blood analyses
Blood samples (20 ml) were drawn monthly from the retro-
orbital sinus and haemoglobin levels were measured using the
HemoCue Hb201+ (HemoCue AB, Sweden). At termination of
the experiments, 500 ml blood was drawn from the mice by
cardiac puncture and processed to serum. A Mouse Adipokine
Multiplex kit (Millipore Lincoresearch, US) was performed to
determine IL-6, insulin, leptin, MCP-1, PAI-I, resistin, and TNF-a
serum levels, while serum iron, triglycerides, total cholesterol, and
HDL were measured using the Vitros 950 Chemistry System.
LDL was calculated from the total cholesterol and HDL levels.
Glucose and insulin tolerance tests
For each test, the mice were fasted for 16 hours and challenged
with 1) an intraperitoneal load of glucose (1 g/kg) for glucose
tolerance testing, or 2) an intraperitoneal load of human insulin
(0.375 IU/kg, Actrapid, Novo Nordic, Denmark) for insulin
tolerance testing. Blood samples (10 ml) were taken retro-orbitally
from conscious mice at 0, 30, 60, 90, 120, and 180 min after
glucose or insulin load. Blood glucose levels were determined using
the HemoCue Glucose 201+ system (HemoCue AB, Sweden).
Homogenate oxidations
Palmitate oxidation was measured in muscle homogenates using
a modified method of that described by Turner et al. [38]. Briefly,
muscles were homogenized in 19 volumes of ice-cold 250 mmol/l
sucrose, 10 mmol/l Tris-HCl, and 1 mmol/l EDTA, pH 7.4. For
assessment of substrate oxidation, 50 ml of muscle homogenate was
incubated with 450 ml reaction mixture (pH 7.4). Final concen-
trations of the reaction mixture were (in mmol/l): 100 sucrose, 80
KCl, 10 Tris-HCl, 5 KH2PO4, 1 MgCl2, 2 malate, 2 ATP, 1
dithiothreitol, 0.2 EDTA, and 0.3% fatty acid–free BSA.
Substrates were 0.2 mmol/l [1–14C]palmitate (0.5 mCi) plus
2 mmol/l L-carnitine and 0.05 mmol/l coenzyme A. After
90 min of incubation at 30uC, the reaction was stopped by the
addition of 100 ml of 1 mol/l perchloric acid. CO2 produced
during the incubation was collected in 100 ml of 1 mol/l NaOH.
For palmitate incubations, 14C counts present in the acid-soluble
fraction were also measured and combined with the CO2 values to
give the total palmitate oxidation rate
RT-qPCR analysis
Total RNA was isolated from frozen muscles, livers, and fat
pads by tissue homogenisation and RNA extraction using the
TRIzol reagent (Invitrogen Life Technologies, Denmark). Mouse
diabetes PCR arrays (PAMM023, SABiosciences) containing pre-
developed reactions for 90 genes were performed according to the
manufacturer’s instructions on muscle samples. Data analysis was
performed using the web-based analysis tool (www.sabiosciences.
com/pcrarraydataanalysis.php), which includes descriptive statis-
tics, including fold change, volcano plots and cluster analyses. For
adipose and liver tissues, RT-PCR was performed using random
p(dN)6 primers (Applied Biosystems, UK) and MultiScripe Reverse
Transcriptase (High Capacity cDNA Reverse Transcription Kit,
Applied Biosystems, UK). All amplifications were done using the
Taqman Universal PCR Master Mix (Applied Biosystems, UK),
and sequence specific primers and Taqman probes. PCR and
detection were performed using the Taqman 7900 (Applied
Biosystems, UK).
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Figure S1 EPO administration induces large increases in Hgb
levels. EPO was administered to groups of 8 mice either by DNA
electrotransfer of 1 mg of EPO plasmid and each of the regulatory
plasmids, pTet-On and pTetS into the right tibialis cranialis
muscle; or by intraperitoneal injections of 10 mg/kg rhEPO. The
mice were placed on either regular chow or a high-fat diet and
means6SEM for each groups are depicted. A) Time course of
hemoglobin levels, and B) serum iron contents measured 12 weeks
after start of treatment. Statistical significance was tested by
Student’s t-test with Bonferroni corrections for multiple testing. *
indicates significance at p,0.05, while ¤ indicates significance at
p,0.01.
Found at: doi:10.1371/journal.pone.0005894.s001 (1.18 MB JPG)
Figure S2 Weight of liver and heart. Twelve weeks after DNA
electrotransfer livers and hearts from EPO transfected mice were
weighed, and means6SEM for groups of 8 mice are shown.
Statistical significance was tested by Student’s t-test with
Bonferroni corrections for multiple testing, and there were no
significant difference between the groups.
Found at: doi:10.1371/journal.pone.0005894.s002 (0.68 MB JPG)
Figure S3 The improvement in glucose tolerance is reversed
when EPO expression is withdrawn. Fourteen weeks after
doxycycline withdrawal in EPO transfected mice, a glucose
tolerance test was performed. There was no difference in the
glucose tolerance between the control and EPO transfected high-
fat fed mice.
Found at: doi:10.1371/journal.pone.0005894.s003 (1.49 MB TIF)
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